Clinical Trials Logo

Filter by:
NCT ID: NCT05077514 Completed - Suicidal Ideation Clinical Trials

Treatment Seeking Study

Start date: March 1, 2012
Phase: N/A
Study type: Interventional

The study team conducted a randomized controlled clinical trial of 809 military service members who were at increased risk for suicide but not currently in behavioral health treatment. This study tested the effectiveness of a brief phone-based intervention (CBT-TS) aimed at changing military member's perceptions about behavioral health therapy. Participants completed five interviews over the course of one year to collect information about change in behavioral health symptoms and treatment utilization.

NCT ID: NCT05077293 Completed - Heart Failure Clinical Trials

Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure

BETTER CARE-HF
Start date: September 9, 2021
Phase:
Study type: Observational

This is a feasibility study using a cross-over design to implement and compare a best practice alert (BPA) with an automated in-basket message to inform providers when a patient with heart failure and reduced ejection fraction (HFrEF) is not on appropriate medical therapy. The data from this pilot study will lead to a randomized controlled trial to compare the effectiveness of the BPA versus an automated in-basket message, versus usual care (no intervention).

NCT ID: NCT05076890 Completed - Clinical trials for Absorption; Chemicals

Hemp 15 mg & 50 mg Capsule Absorption

Start date: August 26, 2021
Phase: N/A
Study type: Interventional

This study is intended to investigate the absorption of cannabidiol (CBD) and cannabidiol acid (CBD-A) in plasma from an oral delivery of a single dose of full spectrum hemp extract at two concentrations over a 4-hour timeline.

NCT ID: NCT05076877 Completed - Healthy Clinical Trials

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

Start date: September 17, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of steady-state concentrations of lazertinib on the single-dose pharmacokinetics (PK) of probe substrates (midazolam, rosuvastatin, and metformin) in healthy adult participants.

NCT ID: NCT05076734 Completed - Pregnancy Related Clinical Trials

Cell- Based Noninvasive Prenatal Testing (NIPT): Single Cell Prenatal Diagnosis (SCPD)

NIPT & SCPD
Start date: June 12, 2020
Phase: N/A
Study type: Interventional

The purpose of the overall study is to develop improved methods for recovery of fetal cells from the mother's blood in order to develop a clinically useful form of cell-based, diagnostic, noninvasive prenatal testing (NIPT). Luna Genetics will analyze blood samples from healthy pregnant women. A phlebotomist will be sent to any location in the United States to collect the blood sample. Sample identifiers will be removed as the first step so that laboratory personnel will not see or have access to identifiers. No information will go back to patients or their physicians.

NCT ID: NCT05076578 Completed - Chronic Wound Clinical Trials

A Prospective Clinical Study Evaluating the Harvesting of Micografts

Start date: September 13, 2021
Phase: N/A
Study type: Interventional

ART (Autologous Regeneration of Tissue) is a revolutionary technology for harvesting skin without the drawbacks of conventional grafting. This innovative system allows the clinician to collect hundreds of microcolumns of full-thickness skin tissue and apply them directly to the wound site. It can all be done in an outpatient setting with minimized donor site concerns.

NCT ID: NCT05076487 Completed - Obesity Clinical Trials

Effects of Episodic Food Insecurity in African American Women With Obesity

RESPONSES
Start date: November 1, 2021
Phase:
Study type: Observational

The objective of this exploratory/developmental study is to investigate the episodic nature of food insecurity as a stressor via responses in body weight and psychological and physiological parameters longitudinally. Sixty African American women with obesity will be enrolled. Pennington Biomedical Research Center will coordinate this longitudinal study and measure 1) daily body weight remotely over 22 weeks and 2) psychological and physiological parameters via clinic assessments at the beginning and end of 22 weeks as well as assess episodes of food insecurity and stress on a weekly basis.

NCT ID: NCT05076149 Completed - Cystic Fibrosis Clinical Trials

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Start date: October 27, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and no F508del mutation.

NCT ID: NCT05076006 Completed - Clinical trials for Cicatricial Alopecia

Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

Start date: May 19, 2021
Phase: Phase 2
Study type: Interventional

Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly destroyed. CA leads to scarred areas, most commonly on the scalp, that cannot re-grow hair. Despite being a long-term condition, that often has significant impact on patients' well-being, available effective treatments for these diseases are lacking. In addition, the molecular abnormalities causing CA are largely unknown. The study team's research involves administrating patients a new investigational drug (a combined TYK/JAK inhibitor) which has been shown to be safe and well tolerated in clinical studies to date, and is being investigated in other conditions, such as AA. CA patients will be asked to provide small samples of skin and blood throughout the treatment period, to find out how they respond to the drug, and to attempt to better understand these diseases.

NCT ID: NCT05075889 Completed - Bone Tumor Clinical Trials

Utility of ICG in Benign Bone Tumors

Start date: November 11, 2021
Phase: Early Phase 1
Study type: Interventional

Patients with a biopsy-proven benign bone tumor for which standard of care is intralesional operative management will receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) the day prior to surgery during their standard pre-operative clinic visit. On the day of surgery, fluorescence images will be obtained using a non-invasive fluorescence camera.